Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer

Yu,Haizhong; Yuan,Jianfen; Xiao,Chunhong; Qin,Yi

doi:10.3892/ijmm.2013.1296

Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer

Authors:
- Haizhong Yu
- Jianfen Yuan
- Chunhong Xiao
- Yi Qin
View Affiliations

Affiliations: Department of Clinical Laboratory of the Traditional Chinese Medical Hospital of Nantong City, Nantong, Jiangsu, P.R. China, Department of Clinical Laboratory of Nantong Tumor Hospital, Nantong, Jiangsu, P.R. China
Published online on: March 11, 2013 https://doi.org/10.3892/ijmm.2013.1296
Pages: 1248-1254

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Recepteur d'origine nantais (RON) is a receptor tyrosine kinase (RTK) normally expressed at low levels in epithelial cells. RON is a 180-kDa heterodimeric protein composed of a 40-kDa α-chain and a 150-kDa transmembrane β-chain with intrinsic tyrosine kinase activity. The extracellular sequences of RON contain several domains including an N-terminal semaphorin (sema) domain, followed by the plexin, semaphorin, integrin (PSI) domain, and four immunoglobulin, plexin, transcription factor (IPT) domains. Here, we identified RON genes from 14 vertebrate genomes and found that RON exists in all types of vertebrates including fish, amphibians, birds and mammals. We found that the human RON gene showed predominant expression in the liver, lymph node, thymus, intestine, lung, mammary gland, bone marrow, brain, heart, placenta, bladder, cortex, cervix, skin, kidney and prostate. When searched in the PrognoScan database, human RON was also found to be expressed in bladder, blood, breast, glioma, esophageal, colorectal, head and neck, ovarian, lung and skin cancer. The relationship between the expression of RON and prognosis was found to vary in different cancer types, even in the same cancer from different databases. This suggests that the function of RON in these tumors may be multidimensional, not just as a tumor suppressor or oncogene. Six available single-nucleotide polymorphisms (SNPs) disrupting existing exonic splicing enhancers were identified in RON. This may contribute to the generation of active RON variants by alternative splicing, which is frequently observed in primary tumors.

View Figures

View References

1	Ronsin C, Muscatelli F, Mattei MG and Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene. 8:1195–1202. 1993.PubMed/NCBI
2	Gaudino G, Avantaggiato V, Follenzi A, Acampora D, Simeone A and Comoglio PM: The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene. 11:2627–2637. 1995.PubMed/NCBI
3	Angeloni D, Danilkovitch-Miagkova A, Ivano SV, Breathnach R, Johnson BE, Leonard EJ and Lerman MI: Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples. Genes Chromosomes Cancer. 29:147–156. 2000. View Article : Google Scholar : PubMed/NCBI
4	Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI
5	Gaudino G, Follenzi A, Naldini L, et al: RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J. 13:3524–3532. 1994.PubMed/NCBI
6	Wang MH, Ronsin C, Gesnel MC, Coupey L, Skeel A, Leonard EJ and Breathnach R: Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science. 266:117–119. 1994. View Article : Google Scholar : PubMed/NCBI
7	Stella GM, Benvenuti S and Comoglio PM: Targeting the MET oncogene in cancer and metastases. Expert Opin Investig Drugs. 19:1381–1394. 2010. View Article : Google Scholar : PubMed/NCBI
8	Medico E, Mongiovi AM, Huff J, Jelinek MA, Follenzi A, Gaudino G, Parsons JT and Comoglio PM: The tyrosine kinase receptors Ron and Sea control ‘scattering’ and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell. 7:495–504. 1996.
9	Wang MH, Lee W, Luo YL, Weis MT and Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol. 213:402–411. 2007. View Article : Google Scholar
10	Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, Hooper AT, Pereira DS, Hicklin DJ and Ellis LM: Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer. 109:1030–1039. 2007. View Article : Google Scholar : PubMed/NCBI
11	Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S and Biamonti G: Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 20:881–890. 2005. View Article : Google Scholar : PubMed/NCBI
12	Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 257:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
13	Moon H, Cho S, Yang X, Zhou J, Loh TJ, Zheng X and Shen H: Identification of novel splicing variants from RON proto-oncogene pre-mRNA. Oncol Rep. 28:2217–2220. 2012.PubMed/NCBI
14	Okino T, Egami H, Ohmachi H, Takai E, Tamori Y, Nakagawa K, Nakano S, Akagi J, Sakamoto O, Suda T and Ogawa M: Presence of RON receptor tyrosine kinase and its splicing variant in malignant and non-malignant human colonic mucosa. Int J Oncol. 15:709–714. 1999.PubMed/NCBI
15	Yang L, Luo Y and Wei J: Integrative genomic analyses on Ikaros and its expression related to solid cancer prognosis. Oncol Rep. 24:571–577. 2010. View Article : Google Scholar : PubMed/NCBI
16	Yang L, Luo Y, Wei J and He S: Integrative genomic analyses on IL28RA, the common receptor of interferon-λ1, -λ2 and -λ3. Int J Mol Med. 25:807–812. 2010.PubMed/NCBI
17	Yang L, Wei J and He S: Integrative genomic analyses on interferon-λs and their roles in cancer prediction. Int J Mol Med. 25:299–304. 2010.
18	Thompson JD, Gibson TJ, Plewniak F, Jeanmougin F and Higgins DG: The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 15:4876–4882. 1997. View Article : Google Scholar : PubMed/NCBI
19	Guindon S, Lethiec F, Duroux P and Gascuel O: PHYML Online - a web server for fast maximum likelihood-based phylogenetic inference. Nucleic Acids Res. 33:W557–W559. 2005. View Article : Google Scholar : PubMed/NCBI
20	Kumar S, Tamura K and Nei M: MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform. 5:150–163. 2004. View Article : Google Scholar
21	Yang Z: PAML: a program package for phylogenetic analysis by maximum likelihood. Comput Appl Biosci. 13:555–556. 1997.PubMed/NCBI
22	Yang Z, Nielsen R, Goldman N and Pedersen AM: Codon-substitution models for heterogeneous selection pressure at amino acid sites. Genetics. 155:431–449. 2000.PubMed/NCBI
23	Katoh Y and Katoh M: Integrative genomic analyses on GLI1: Positive regulation of GLI1 by Hedgehog-GLI, TGFβ-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int J Oncol. 35:187–192. 2009.PubMed/NCBI
24	Katoh Y and Katoh M: Integrative genomic analyses on GLI2: Mechanism of Hedgehog priming through basal GLI2 expression, and interaction map of stem cell signaling network with P53. Int J Oncol. 33:881–886. 2008.PubMed/NCBI
25	Katoh Y and Katoh M: Integrative genomic analyses of WNT11: Transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling. Int J Mol Med. 24:247–251. 2009. View Article : Google Scholar : PubMed/NCBI
26	Katoh M and Katoh M: Transcriptional mechanisms of WNT5A based on NF-κB, Hedgehog, TGFβ, and Notch signaling cascades. Int J Mol Med. 23:763–769. 2009.PubMed/NCBI
27	Katoh M and Katoh M: Integrative genomic analyses of ZEB2: Transcriptional regulation of ZEB2 based on SMADs, ETS1, HIF1α, POU/OCT, and NF-κB. Int J Oncol. 34:1737–1742. 2009.PubMed/NCBI
28	Katoh M and Katoh M: Transcriptional regulation of WNT2B based on the balance of Hedgehog, Notch, BMP and WNT signals. Int J Oncol. 34:1411–1415. 2009.PubMed/NCBI
29	Chalifa-Caspi V, Yanai I, Ophir R, Rosen N, Shmoish M, Benjamin-Rodrig H, Shklar M, Stein TI, Shmueli O, Safran M and Lancet D: GeneAnnot: comprehensive two-way linking between oligonucleotide array probesets and GeneCards genes. Bioinformatics. 20:1457–1458. 2004. View Article : Google Scholar : PubMed/NCBI
30	Parkinson H, Sarkans U, Shojatalab M, Abeygunawardena N, Contrino S, Coulson R, Farne A, Lara GG, Holloway E, Kapushesky M, Lilja P, Mukherjee G, Oezcimen A, Rayner T, Rocca-Serra P, Sharma A, Sansone S and Brazma A: ArrayExpress - a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 33:D553–D555. 2005. View Article : Google Scholar : PubMed/NCBI
31	Mizuno H, Kitada K, Nakai K and Sarai A: PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med Genomics. 2:182009. View Article : Google Scholar : PubMed/NCBI
32	Benvenuti S and Comoglio PM: The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol. 213:316–325. 2007. View Article : Google Scholar : PubMed/NCBI
33	Wagh PK, Peace BE and Waltz SE: Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res. 100:1–33. 2008. View Article : Google Scholar : PubMed/NCBI
34	Maggiora P, Marchio S, Stella MC, Giai M, Belfiore A, De Bortoli M, Di Renzo MF, Costantino A, Sismondi P and Comoglio PM: Overexpression of the RON gene in human breast carcinoma. Oncogene. 16:2927–2933. 1998. View Article : Google Scholar : PubMed/NCBI
35	Park JS, Park JH, Lee S, Joo YE and Jung YD: Small interfering RNA targeting of Recepteur d’Origine Nantais induces apoptosis via modulation of nuclear factor-κB and Bcl-2 family in gastric cancer cells. Oncol Rep. 24:709–714. 2010.
36	Jiang WG, Ye L, Ablin RJ, Kynaston HG and Mason MD: The prostate transglutaminase, TGase-4, coordinates with the HGFL/MSP-RON system in stimulating the migration of prostate cancer cells. Int J Oncol. 37:413–418. 2010. View Article : Google Scholar : PubMed/NCBI
37	Zhou YQ, He C, Chen YQ, Wang D and Wang MH: Altered expression of the RON receptor tyrosine kniase in primary human colorectal adenocarcinomas: generation of different splicing variants and their oncogenic potential. Oncogene. 22:186–197. 2003. View Article : Google Scholar
38	Lee WY, Chen HH, Chow NH, Su WC, Lin PW and Guo HR: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res. 11:2222–2228. 2005. View Article : Google Scholar : PubMed/NCBI
39	Cheng HL, Liu HS, Lin YJ, Chen HH, Hsu PY, Chang TY, Ho CL, Tzai TS and Chow NH: Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br J Cancer. 92:1906–1914. 2005. View Article : Google Scholar : PubMed/NCBI
40	Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM and Flavia Di Renzo M: The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res. 288:382–389. 2003. View Article : Google Scholar : PubMed/NCBI
41	Wang MH, Padhye SS, Guin S, Ma Q and Zhou YQ: Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin. 31:1181–1188. 2010. View Article : Google Scholar : PubMed/NCBI
42	Cho SB, Park YL, Song YA, Kim KY, Lee GH, Cho DH, Myung DS, Park KJ, Lee WS, Chung IJ, Choi SK, Kim KK and Joo YE: Small interfering RNA-directed targeting of RON alters invasive and oncogenic phenotypes of human hepatocellular carcinoma cells. Oncol Rep. 26:1581–1586. 2011.PubMed/NCBI
43	Saigusa S, Toiyama Y, Tanaka K, Yokoe T, Fujikawa H, Matsushita K, Okugawa Y, Inoue Y, Uchida K, Mohri Y and Kusunoki M: Inhibition of HGF/cMET expression prevents distant recurrence of rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 40:583–591. 2012.
44	Li Z, Yao H, Guin S, Padhye SS, Zhou YQ and Wang MH: Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells. Int J Oncol. 37:473–482. 2010.PubMed/NCBI
45	Ma Q, Zhang K, Yao HP, Zhou YQ, Padhye S and Wang MH: Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence. Int J Oncol. 36:1551–1561. 2010.PubMed/NCBI
46	Ma Q, Zhang K, Guin S, Zhou YQ and Wang MH: Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor tyrosine kinase. Mol Cancer. 9:3072010. View Article : Google Scholar
47	Parra E, Ferreira J and Saenz L: Inhibition of Egr-1 by siRNA in prostate carcinoma cell lines is associated with decreased expression of AP-1 and NF-κB. Int J Mol Med. 28:847–853. 2011.PubMed/NCBI
48	Hwang JT, Park OJ, Lee YK, Sung MJ, Hur HJ, Kim MS, Ha JH and Kwon DY: Anti-tumor effect of luteolin is accompanied by AMP-activated protein kinase and nuclear factor-κB modulation in HepG2 hepatocarcinoma cells. Int J Mol Med. 28:25–31. 2011.PubMed/NCBI
49	Seol JW, Lee YJ, Jackson CJ, Sambrook PN and Park SY: Activated protein C inhibits bisphosphonate-induced endothelial cell death via the endothelial protein C receptor and nuclear factor-κB pathways. Int J Mol Med. 27:835–840. 2011.PubMed/NCBI
50	Hayashi S, Sakurai H, Hayashi A, Tanaka Y, Hatashita M and Shioura H: Inhibition of NF-κB by combination therapy with parthenolide and hyperthermia and kinetics of apoptosis induction and cell cycle arrest in human lung adenocarcinoma cells. Int J Mol Med. 25:81–87. 2010.
51	Hou L, Xu B, Mohankumar KM, Goffin V, Perry JK, Lobie PE and Liu DX: The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells. Int J Oncol. 41:2285–2295. 2012.PubMed/NCBI
52	Naher L, Kiyoshima T, Kobayashi I, Wada H, Nagata K, Fujiwara H, Ookuma YF, Ozeki S, Nakamura S and Sakai H: STAT3 signal transduction through interleukin-22 in oral squamous cell carcinoma. Int J Oncol. 41:1577–1586. 2012.PubMed/NCBI
53	Umehara S, Fujiwara H, Shiozaki A, Todo M, Furutani A, Yoneda M, Ikai A, Tada H, Komatsu S, Ichikawa D, Okamoto K, Ochiai T, Kokuba Y and Otsuji E: PSK induces apoptosis through the inhibition of activated STAT3 in human esophageal carcinoma cells. Int J Oncol. 41:61–66. 2012.PubMed/NCBI
54	Kwon CY, Kim KR, Choi HN, Chung MJ, Noh SJ, Kim DG, Kang MJ, Lee DG and Moon WS: The role of serum response factor in hepatocellular carcinoma: Implications for disease progression. Int J Oncol. 37:837–844. 2010.PubMed/NCBI
55	Kim HJ, Kim KR, Park HS, Jang KY, Chung MJ, Shong M and Moon WS: The expression and role of serum response factor in papillary carcinoma of the thyroid. Int J Oncol. 35:49–55. 2009.PubMed/NCBI
56	Park MY, Kim KR, Park HS, Park BH, Choi HN, Jang KY, Chung MJ, Kang MJ, Lee DG and Moon WS: Expression of the serum response factor in hepatocellular carcinoma: Implications for epithelial-mesenchymal transition. Int J Oncol. 31:1309–1315. 2007.PubMed/NCBI
57	Collet N, Théoleyre S, Rageul J, Mottier S, Jouan F, Rioux-Leclercq N, Fergelot P, Patard JJ, Masson D and Denis MG: PPARγ is functionally expressed in clear cell renal cell carcinoma. Int J Oncol. 38:851–857. 2011.
58	Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T and Sata M: PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol. 40:679–685. 2012.
59	Mansour M, Schwartz D, Judd R, Akingbemi B, Braden T, Morrison E, Dennis J, Bartol F, Hazi A, Napier I and Abdel-Mageed AB: Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer. Int J Oncol. 38:537–546. 2011.
60	Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, Jeong P, Kim MJ, Yun SJ, Lee KM, Moon SK, Lee SC, Cha EJ and Bae SC: Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer. 9:32010. View Article : Google Scholar : PubMed/NCBI
61	Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ and Chu IS: Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumors. J Clin Oncol. 28:2660–2667. 2010. View Article : Google Scholar : PubMed/NCBI
62	Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT, Black PM, von Deimling A, Pomeroy SL, Golub TR and Louis DN: Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63:1602–1607. 2003.PubMed/NCBI
63	Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA and Sotiriou C: PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 107:10208–10213. 2010. View Article : Google Scholar : PubMed/NCBI
64	Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y and Foekens JA: The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat. 116:303–309. 2009. View Article : Google Scholar : PubMed/NCBI
65	Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, MacGrogan G, Mauriac L, Katsaros D, Molina F, Theillet C and Darbon JM: A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res. 14:1744–1752. 2008. View Article : Google Scholar : PubMed/NCBI
66	Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J, Kuznetsov VA and Miller LD: Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 66:10292–10301. 2006. View Article : Google Scholar : PubMed/NCBI
67	Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M and Sotiriou C; TRANSBIG Consortium. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 13:3207–3214. 2007. View Article : Google Scholar : PubMed/NCBI
68	Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, Hupe P, Plancher C, Reyes C, Albaud B, Rapinat A, Gentien D, Couturier J, Sastre-Garau X, Desjardins L, Thiery JP, Roman-Roman S, Asselain B, Barillot E, Piperno-Neumann S and Saule S: High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res. 71:666–674. 2011. View Article : Google Scholar : PubMed/NCBI
69	Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, Lin L, Chen G, Gharib TG, Thomas DG, Lizyness ML, Kuick R, Hayasaka S, Taylor JM, Iannettoni MD, Orringer MB and Hanash S: Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 8:816–824. 2002.PubMed/NCBI
70	Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, Thomas RK, Naoki K, Ladd-Acosta C, Liu N, Pintilie M, Der S, Seymour L, Jurisica I, Shepherd FA and Tsao MS: Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 28:4417–4424. 2010. View Article : Google Scholar : PubMed/NCBI
71	Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Kotera K, Masuzaki H, Tashiro H, Katabuchi H, Inoue I and Tanaka K: Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One. 5:e96152010. View Article : Google Scholar : PubMed/NCBI